title: Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation.
abstract: IL-17 is involved in inducing and mediating pro-inflammatory responses. The association of IL-17 with tumor growth or graft-versus-host disease (GVHD) has become a subject of controversy. We hypothesized that serum IL-17 (sIL-17) levels during the peri-transplant period may affect alloreactive responses after allogeneic stem cell transplantation (SCT). sIL-17 levels of 95 patients with leukemia who had undergone myeloablative allogeneic SCT were measured using ELISA before conditioning and on day 0, +7, and +14 after transplantation. With a median follow-up of 17 months, the overall survival, disease-free survival, non-relapse mortality, and relapse incidence were 70.9%, 66.3%, 10.3%, and 23.4%, respectively. Ten patients relapsed within 180 days (early relapse, 10.5%) post-transplant. The cumulative incidence of acute GVHD over grade II and chronic GVHD was 55.8% and 69.0%, respectively. Analyses using repeated measures of ANOVA and mean values of sIL-17 revealed that patients relapsed within 180 days had higher sIL-17 levels, whereas no association existed between sIL-17 levels and other clinical outcomes, including acute GVHD. Receiver operating characteristic curve analyses also revealed that sIL-17 levels were available for the prediction of early relapse and that patients with higher sIL-17 levels at each time point had a significantly higher early relapse. Multivariate analyses and subgroup analyses with only standard disease status suggest the association of sIL-17 levels with subsequent early relapse independent of disease status at transplantation. This study is the first one demonstrating the early change in sIL-17 during the peri-transplant period and the association with early relapse in humans.
authors: Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, South Korea.
authors: Byung-Sik
authors: BS
authors: Cho
authors: Ji-Young
authors: JY
authors: Lim
authors: Seung-Ah
authors: SA
authors: Yahng
authors: Sung-Eun
authors: SE
authors: Lee
authors: Ki-Seong
authors: KS
authors: Eom
authors: Yoo-Jin
authors: YJ
authors: Kim
authors: Nak-Gyun
authors: NG
authors: Chung
authors: Dae-Chul
authors: DC
authors: Jeong
authors: Seok
authors: S
authors: Lee
authors: Hee-Je
authors: HJ
authors: Kim
authors: Seok-Goo
authors: SG
authors: Cho
authors: Dong-Wook
authors: DW
authors: Kim
authors: Jong-Wook
authors: JW
authors: Lee
authors: Woo-Sung
authors: WS
authors: Min
authors: Chong-Won
authors: CW
authors: Park
authors: Chang-Ki
authors: CK
authors: Min
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D019540:Area Under Curve; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000097:blood / Q000453:epidemiology / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D020381:Interleukin-17 / Q000097:blood* / Q000276:immunology; D007938:Leukemia / Q000097:blood / Q000276:immunology / Q000517:prevention & control* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000276:immunology / Q000379:methods*; D055815:Young Adult
chemical_list: D020381:Interleukin-17